JPWO2021037972A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021037972A5
JPWO2021037972A5 JP2022513127A JP2022513127A JPWO2021037972A5 JP WO2021037972 A5 JPWO2021037972 A5 JP WO2021037972A5 JP 2022513127 A JP2022513127 A JP 2022513127A JP 2022513127 A JP2022513127 A JP 2022513127A JP WO2021037972 A5 JPWO2021037972 A5 JP WO2021037972A5
Authority
JP
Japan
Prior art keywords
seq
dsrna
optionally
group
sense strand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546040A (ja
JP2022546040A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/073961 external-priority patent/WO2021037972A1/en
Publication of JP2022546040A publication Critical patent/JP2022546040A/ja
Publication of JP2022546040A5 publication Critical patent/JP2022546040A5/ja
Publication of JPWO2021037972A5 publication Critical patent/JPWO2021037972A5/ja
Priority to JP2024180454A priority Critical patent/JP2025013845A/ja
Pending legal-status Critical Current

Links

JP2022513127A 2019-08-27 2020-08-27 Ｐｃｓｋ９を阻害するための組成物および方法 Pending JP2022546040A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180454A JP2025013845A (ja) 2019-08-27 2024-10-16 Ｐｃｓｋ９を阻害するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306036.5 2019-08-27
EP19306036 2019-08-27
PCT/EP2020/073961 WO2021037972A1 (en) 2019-08-27 2020-08-27 Compositions and methods for inhibiting pcsk9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180454A Division JP2025013845A (ja) 2019-08-27 2024-10-16 Ｐｃｓｋ９を阻害するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022546040A JP2022546040A (ja) 2022-11-02
JP2022546040A5 JP2022546040A5 (https=) 2023-09-04
JPWO2021037972A5 true JPWO2021037972A5 (https=) 2023-09-04

Family

ID=67956661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513127A Pending JP2022546040A (ja) 2019-08-27 2020-08-27 Ｐｃｓｋ９を阻害するための組成物および方法
JP2024180454A Pending JP2025013845A (ja) 2019-08-27 2024-10-16 Ｐｃｓｋ９を阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180454A Pending JP2025013845A (ja) 2019-08-27 2024-10-16 Ｐｃｓｋ９を阻害するための組成物および方法

Country Status (5)

Country Link
US (1) US20220290156A1 (https=)
EP (1) EP4022061A1 (https=)
JP (2) JP2022546040A (https=)
CN (1) CN115176011B (https=)
WO (1) WO2021037972A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
EP3884051A2 (en) 2018-11-23 2021-09-29 Sanofi Novel rna compositions and methods for inhibiting angptl8
JP7667775B2 (ja) * 2019-09-05 2025-04-23 サノフイ ヌクレオチド類似体を含有するオリゴヌクレオチド
WO2024002006A1 (zh) * 2022-06-27 2024-01-04 大睿生物医药科技(上海)有限公司 具有增强的稳定性的核苷酸替代物
JP2025532985A (ja) 2022-09-30 2025-10-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド 修飾二本鎖ｒｎａ剤
WO2024228030A2 (en) * 2023-05-04 2024-11-07 Argonaute RNA Limited Dual silencing
CN121866332A (zh) * 2023-06-21 2026-04-14 美国圣因生物股份有限公司 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9（pcsk9）的双链rna及其使用方法
WO2025077949A1 (zh) * 2023-11-06 2025-04-17 杭州天龙药业有限公司 提升双链寡核苷酸靶基因抑制效果的修饰模板及其组合与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
BR9914773A (pt) 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
MXPA01003642A (es) 1998-10-09 2003-07-21 Ingene Inc Sintesis enzimatica de adnss.
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CN100365122C (zh) * 2005-12-30 2008-01-30 中国疾病预防控制中心病毒病预防控制所 针对乙型流感病毒多聚酶基因的siRNA序列及其应用
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
WO2013154766A1 (en) * 2012-04-13 2013-10-17 New York University Microrna control of ldl receptor pathway
US10125369B2 (en) * 2012-12-05 2018-11-13 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA compositions and methods of use thereof
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
EP3762395A1 (en) * 2018-03-07 2021-01-13 Sanofi Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
US11566248B2 (en) * 2018-04-18 2023-01-31 Dicerna Pharmaceuticals, Inc. PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Similar Documents

Publication Publication Date Title
EP2431466B1 (en) Single-strand nucleic acid molecule for controlling gene expression
EP4389891A1 (en) Modified heteronucleic acid containing morpholino nucleic acid
JP2017532038A5 (https=)
CA3057561C (en) RNA INTERFERENCE MEDIATED INHIBITION OF TMPRSS6
EP2436767A1 (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
US7786292B2 (en) Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease
JPWO2022270585A5 (https=)
JP2009513144A5 (https=)
EP3230453B1 (en) Downregulating mir-132 for the treatment of lipid related disorders
JPWO2021037972A5 (https=)
CN113164768B (zh) 用于抑制tmprss6表达的核酸和铁螯合剂
JPWO2020041769A5 (https=)
JPWO2020205605A5 (https=)
EP3532617A1 (en) Antisense oligonucleotides
JPWO2020104649A5 (https=)
JP6974872B2 (ja) ヘテロ二本鎖型ａｎｔｉｍｉＲ
JPWO2021044004A5 (https=)
JPH09104629A (ja) ウイルムス腫瘍遺伝子（ｗｔ１）に対するアンチセンスオリゴヌクレオチド誘導体を含んで成る白血病細胞増殖阻害剤
CN119552122B (zh) 5'-磷酸酯修饰核苷及其制备方法与应用
WO2025201529A1 (en) Compounds for synthesizing modified small activating rna molecules, modified small activating rna molecules and uses thereof
JP2017046596A (ja) ＴＧＦ−β１遺伝子発現制御のための一本鎖核酸分子
EP4446414A1 (en) Antisense oligonucleotide complex
US20240240183A1 (en) Heteronucleic acid containing scpBNA or AmNA
EP3235906B1 (en) Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
RU2025110478A (ru) КОМПОЗИЦИИ миРНК И СПОСОБЫ ДЛЯ НАЦЕЛИВАНИЯ НА НУКЛЕИНОВЫЕ КИСЛОТЫ АЛЬФА-СИНУКЛЕИНА